Expert Interpretation.
Confident Decisions.
Turn complex genomic reports into clear, evidence-ranked treatment options — with molecular tumour board support, trial matching and a specialist on call for your hardest cases.
How We Support Your Practice
Specialist molecular oncology input that fits around your clinic, not the other way round.
Oncogenomic Interpretation
Tiered interpretation of CGP, panels, RNA, ctDNA and germline results — with CHIP, subclonal and copy-number calls placed in context.
Molecular Tumour Board
Present your case to a multidisciplinary board and receive a structured consensus report with rationale and evidence levels.
Trial & Access Matching
Biomarker-matched trials, expanded-access and off-label options ranked by eligibility, distance and evidence.
Resistance & Rare Cases
Acquired resistance, reversion mutations, rare fusions, CUP and tumour-agnostic biomarkers — reviewed by specialists.
AI-Human Integrated Interpretation
Combining the power of AI with expert clinical judgement.
AI-powered Analysis
- Literature and guideline search
- Variant annotation & classification
- Clinical trial matching
- Tumour biology & pathway analysis
- Evidence summarisation
Expert Review
- Clinical context integration
- Treatment relevance assessment
- Complex variant interpretation
- Multidisciplinary discussion
- Final expert report
How It Works
Tests We Interpret
Expert interpretation across a wide range of genomic and molecular tests.
Comprehensive Genomic Profiling
Solid tumours & haematological malignancies
Targeted Gene Panels
Curated and custom panels
RNA Sequencing
Fusions, exon skipping and expression
MRD & ctDNA
Minimal residual disease and monitoring
Biomarkers & IHC
Integrated genomic, pathology and IHC
See What a Dr PreZiGen Interpretation Looks Like
One page that brings the whole case together — clinical timeline, tiered genomic findings, key biomarkers and the Dr PreZiGen Drug Score that ranks each treatment option by the strength of its evidence.
- Patient & treatment timeline
- AMP/ASCO/CAP-tiered variants
- HRD, TMB, MSI, DPYD at a glance
- Evidence-weighted Drug Score
- Actionable additional recommendations
- Full literature references
Our Focus Areas
Broad expertise across solid tumours and haematological malignancies.
Education for Your Team
- Case-based CME sessions on biomarker-driven oncology
- Reading a CGP report — tiers, VAF, CHIP and copy number
- ctDNA, MRD and resistance monitoring in practice
- Journal clubs on new approvals and practice-changing trials
A Molecular Oncologist in Your Corner.
Send us your most challenging case — we'll return a clear, referenced interpretation you can act on.